Vinona Muralidaran

This paper develops GPC3-targeted CAR T cells resistant to immunosuppressive drugs and with reduced alloreactivity, showing efficacy in preclinical models and feasibility for clinical use post-liver transplantation.

The paper uses cfDNA methylation patterns to detect allograft injury after liver transplants and identifies early-onset injury through sustained cfDNA elevation.